Mycoplasma pneumoniae

Mycoplasma pneumoniae is a species of extremely small bacteria. It belongs to the class Mollicutes, a group named for their "soft skin" because they lack a cell wall. This bacterium is a significant human pathogen. It causes a disease known as Mycoplasma pneumonia. This is a form of atypical bacterial pneumonia. It is sometimes related to a condition called cold agglutinin disease. Because it is one of the smallest self-replicating organisms, it is a major subject of scientific study.

The biological structure of M. pneumoniae is quite unique. Most bacteria possess a peptidoglycan cell wall for protection. However, M. pneumoniae lacks the genes to build this wall. This absence makes them naturally resistant to antibiotics like beta-lactams. These drugs work by attacking the cell wall. Since the bacterium has no wall, the drugs have nothing to target. To stay stable, the bacterium uses a reinforced cell membrane. This membrane contains sterols, which are fats it obtains from its host.

To live and infect, the bacterium uses a specialized attachment organelle. This structure allows the organism to adhere to cells in the respiratory tract. Once attached, it uses a gliding motility to move. This process helps the bacterium invade host cells. During infection, it can cause cytotoxic effects. These effects include the loss of cilia, which are tiny hair-like structures in the lungs. The bacterium also releases hydrogen peroxide. It produces a specific substance called a CARDS toxin. This toxin contributes to inflammation and respiratory distress.

Scientists have a long history of trying to identify this microbe. In 1898, Nocard and Roux isolated a microorganism linked to cattle pneumonia. These were later called pleuropneumonia-like organisms, or PPLOs. In 1944, Monroe Eaton cultivated an agent in embryonated chicken eggs. This was called the "Eaton agent." Because it grew in eggs, many thought it was a virus. However, antibiotics could treat the infection, which suggested it was actually bacteria. In 1961, Robert Chanock and Leonard Hayflick collaborated to solve the mystery. Hayflick used a special agar and fluid medium to isolate the unique mycoplasma. This proved that the Eaton agent was indeed M. pneumoniae.

The genome of M. pneumoniae is remarkably small. It consists of 816,394 base pairs. Within this genome, there are 687 genes that encode for proteins. About 56.6% of these genes code for essential metabolic enzymes. These enzymes are mostly involved in glycolysis and organic acid fermentation. Because the genome is so reduced, the bacterium is an obligate parasite. It lacks many metabolic pathways, such as the TCA cycle and the respiratory electron transport chain. It also cannot make its own amino acids, fatty acids, or cholesterol. It must import these essential building blocks from its host.

This simplified metabolism has specific consequences for the bacterium. M. pneumoniae has a "linear metabolome." This means it has fewer metabolic reactions than bacteria like E. coli. This makes the organism less adaptable to external changes. Most of its metabolic energy is used just to maintain proton gradients. In fact, up to 80% of its energy goes to this task. Only 12% to 29% of its energy is used for actual cell growth. This is a very low percentage compared to other bacterial species. This efficiency loss is likely an adaptation to its parasitic lifestyle.

Treating M. pneumoniae requires specific types of antibiotics. Doctors typically use macrolides or tetracyclines. These drugs work by inhibiting protein synthesis. However, managing these infections is becoming more difficult. Resistance is increasing, especially in parts of Asia. This resistance is caused by mutations in the 23S rRNA gene. These mutations interfere with how macrolides bind to the bacterium. Scientists must now look for alternative treatment strategies. Understanding the metabolic and genetic makeup of the bacterium is vital for finding these new solutions.